Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination

FASEB Journal

Volumn 26, Issue 3, 2012, Pages 1018-1026

  Cai, Lifeng ^a,b   Pan, Chungen ^a,c   Xu, Liang ^b   Shui, Yuan ^a   Liu, Keliang ^b   Jiang, Shibo ^a,d  

^a NEW YORK BLOOD CENTER   (United States)

^b BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

gp41; Peptide; T1144; T20; TLT

Indexed keywords

ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; T 1144; UNCLASSIFIED DRUG;

ALPHA HELIX; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CIRCULAR DICHROISM; DRUG SYNERGISM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; SEQUENCE HOMOLOGY, AMINO ACID;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84863249782     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.11-195289     Document Type: Article

References (29)

1. Cai, L., and Jiang, S. (2010) Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. ChemMedChem 5, 1813-1824
2. Eckert, D. M., and Kim, P. S. (2001) Mechanisms of viral membrane fusion and its inhibition. Ann. Rev. Biochem. 70, 777-810 (Pubitemid 32662225)
3. Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (Pubitemid 27199898)
4. Jiang, S. B., Lin, K., Strick, N., and Neurath, A. R. (1993) HIV-1 inhibition by a peptide. Nature 365, 113-113
5. Wild, C., Oas, T., McDanal, C., Bolognesi, D., and Matthews, T. (1992) A synthetic peptide inhibitor of human-immunodeficiency-virus replication - correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. U. S. A. 89, 10537-10541
6. Wild, C., Dubay, J. W., Greenwell, T., Baird, T., Oas, T. G., McDanal, C., Hunter, E., and Matthews, T. (1994) Propensity for a leucine zipper-like domain of human-immunodeficiency-virus type-1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. U. S. A. 91, 12676-12680
7. Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., Mathews, T., Johnson, M. R., Nowak, M. A., Shaw, G. M., and Saag, M. S. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4, 1302-1307 (Pubitemid 28512112)
8. Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S. G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., Chung, J., DeMasi, R., Donatacci, L., Drobnes, C., Delehanty, J., and Salgo, M., for the TORO 1 Study Group. (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. New Engl. J. Med. 348, 2175-2185 (Pubitemid 36618128)
9. Delmedico, M., Bray, B., Cammack, N., Davison, D., Dwyer, J., Frick, L., Tvermoes, N., Wring, S., Zhang, H., and Greenberg, M. (2006) Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, USA
10. Liu, S. W., Jing, W. G., Cheung, B., Lu, H., Sun, J., Yan, X. X., Niu, J. K., Farmar, J., Wu, S. G., and Jiang, S. B. (2007) HIV gp41 C-terminal heptad repeat contains multifunctional domains - relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem. 282, 9612-9620 (Pubitemid 47104580)
11. Pan, C. G., Cai, L. F., Lu, H., Qi, Z., and Jiang, S. B. (2009) Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide-sensitive and -resistant HIV type 1 strains. J. Virol. 83, 7862-7872
12. Pan, C., Lu, H., Qi, Z., and Jiang, S. B. (2009) Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors. Aids 23, 639-641
13. Pan, C., Cai, L., Lu, H., Lu, L., and Jiang, S. (2011) A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 with high potency and stability. J. Biol. Chem. 286, 28425-28434
14. Dong, M. X., Zhang, J. A., Peng, X. Q., Lu, H., Yun, L. H., Jiang, S. B., and Dai, Q. Y. (2010) Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents. Eur. J. Med. Chem. 45, 4096-4103
15. Chou, T. (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681
16. Liu, S. W., Zhao, Q., and Jiang, S. B. (2003) Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors. Peptides 24, 1303-1313 (Pubitemid 38045537)
17. Case, D. A., Darden, T. A., Cheatham, T. E., III, .Simmerling, C. L., Wang, J., Duke, R. E., Luo, R., Merz, K. M., Wang, B., Pearlman, D. A., Crowley, M., Brozell, S., Tsui, V., Gohlke, H., Mongan, J., Hornak, V., Cui, G., Beroza, P., Schafmeister, C., Caldwell, J. W., Ross, W. S., and Kollman, P. A. (2004) AMBER 8, University of California, San Francisco
18. Liu, J., Deng, Y. Q., Li, Q. N., Dey, A. K., Moore, J. P., and Lu, M. (2010) Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion. J. Virol. 84, 201-209
19. Cai, L. F., Balogh, E., and Gochin, M. (2009) Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors. Antimicrob. Agents Chemother. 53, 2444-2449
20. Lawless, M. K., Barney, S., Guthrie, K. I., Bucy, T. B., Petteway, S. R., and Merutka, G. (1996) HIV-1 membrane fusion mechanism: Structural studies of the interactions between biologically-active peptides from gp41. Biochemistry 35, 13697-13708 (Pubitemid 26359183)
21. Wild, C., Greenwell, T., Shugars, D., Rimskyclarke, L., and Matthews, T. (1995) The inhibitory activity of an hiv type-1 peptide correlates with its ability to interact with a leucinezipper structure. Aids Res. Hum. Retrov. 11, 323-325
22. Dwyer, J. J., Wilson, K. L., Davison, D. K., Freel, S. A., Seedorff, J. E., Wring, S. A., Tvermoes, N. A., Matthews, T. J., Greenberg, M. L., and Delmedico, M. K. (2007) Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. U. S. A. 104, 12772-12777 (Pubitemid 47255230)
23. Naito, T., Izumi, K., Kodama, E., Sakagami, Y., Kajiwara, K., Nishikawa, H., Watanabe, K., Sarafianos, S. G., Oishi, S., Fujii, N., and Matsuoka, M. (2009) SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob. Agents Chemother. 53, 1013-1018
24. Nishikawa, H., Nakamura, S., Kodama, E., Ito, S., Kajiwara, K., Izumi, K., Sakagami, Y., Oishi, S., Ohkubo, T., Kobayashi, Y., Otaka, A., Fujii, N., and Matsuoka, M. (2009) Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. Int. J. Biochem. Cell Biol. 41, 891-899
25. Nishikawa, H., Oishi, S., Fujita, M., Watanabe, K., Tokiwa, R., Ohno, H., Kodama, E., Izumi, K., Kajiwara, K., Naitoh, T., Matsuoka, M., Otaka, A., and Fujii, N. (2008) Identification of minimal sequence for HIV-1 fusion inhibitors. Bioorg. Med. Chem. 16, 9184-9187
26. Oishi, S., Ito, S., Nishikawa, H., Watanabe, K., Tanaka, M., Ohno, H., Izumi, K., Sakagami, Y., Kodama, E., Matsuoka, M., and Fujii, N. (2008) Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity. J. Med. Chem. 51, 388-391 (Pubitemid 351252265)
27. Otaka, A., Nakamura, M., Nameki, D., Kodama, E., Uchiyama, S., Nakamura, S., Nakano, H., Tamamura, H., Kobayashi, Y., Matsuoka, M., and Fujii, N. (2002) Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew. Chem. Int. Ed. 41, 2938-2940 (Pubitemid 34966553)
28. Steger, H. K., and Root, M. J. (2006) Kinetic dependence to HIV-1 entry inhibition. J. Biol. Chem. 281, 25813-25821 (Pubitemid 44401969)
29. Kahle, K. M., Steger, H. K., and Root, M. J. (2009) Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathogens 5